Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European schizophrenia outpatient health outcomes study

Journal of Nervous and Mental Disease

Volumn 200, Issue 7, 2012, Pages 637-643

  Novick, Diego ^a,b   Ascher Svanum, Haya ^a   Brugnoli, Roberto ^c   Bertsch, Jordan ^d   Hong, Jihyung ^a   Haro, Josep Maria ^d  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Fondazione Italiana per lo studio della Schizophrenia   (Italy)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antipsychotics; combination therapy; monotherapy; polypharmacy; schizophrenia

Indexed keywords

AMISULPRIDE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; DISEASE DURATION; DISEASE SEVERITY; EUROPE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; POLYPHARMACY; POST HOC ANALYSIS; PROSPECTIVE STUDY; SCHIZOPHRENIA; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; EUROPE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; POLYPHARMACY; PROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE; TIME FACTORS;

EID: 84863649613     PISSN: 00223018     EISSN: 1539736X     Source Type: Journal    
DOI: 10.1097/NMD.0b013e31825bfd95     Document Type: Article

References (35)

1. American Psychiatric Association (2004) Practice guidelines for the treatment of patients with schizophrenia, 2nd edition. Am J Psychiatry. 161:1-56.
2. Barnes TR (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 25:567-620.
3. Chernick MR (1999) Bootstrap methods: A practitioner's guide. New York: John Wiley & Sons, Inc.
4. Chiles JA, Miller AL, Crismon LM, Rush AJ, Krasnoff AS, Shon SS (1999) The Texas medication algorithm project: Development and implementation of the schizophrenia algorithm. Psychiatr Serv. 50:69-74.
5. Correll CU, Kane JM, O'Shea D, Razi K, Malhotra AK (2003) Antipsychotic polypharmacy in the treatment of schizophrenia. Schizophr Res. 60(Suppl. 1):37.
6. Covell NH, Jackson CT, Evans AC, Essock SM (2002) Antipsychotic prescribing practices in Connecticut's Public Mental Health System: Rates of changing medications and prescribing styles. Schizophr Bull. 28:17-29.
7. Expert Consensus Guideline Series (1999) Treatment of schizophrenia. J Clin Psychiatry. 60(Suppl. 11):3-80.
8. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 5:26.
9. Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 106:323-330.
10. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 65: 1377-1388.
11. Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey J (2004) The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health. 7:22-35.
12. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J (2009) Advantages and disadvantages of combination treatment with antipsychotics. ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol. 19:520-532.
13. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, Wright P, Knapp M; SOHO Study Group (2003) The European Schizophrenia Outpatient Health Outcome (SOHO) study: Rationale, methods and recruitment. Acta Psychiatrica Scand. 107:222-232.
14. Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M; SOHO Study Group (2006) Remission and relapse in the outpatient care of schizophrenia: Three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 26:571-578.
15. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D; SOHO Study Group (2007) Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results. Eur Neuropsychopharmacol. 17:235-244.
16. Jaffe AB, Levine J (2003) Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf. 12:41-48.
17. Jerrell JM (2002) Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull. 28:589-605.
18. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, GaebelW, Peuskens J, Lindefors N, Riecher-Rö ssler A, Grobbee DE; EUFEST Study Group (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet. 371:1085-1097.
19. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, TenhulaWN, Boerescu D, Tek C, Sandson N, SteinwachsDM (2004) The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophr Bull. 30:193-217.
20. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 166:152-163.
21. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 353:1209-1223.
22. Loosbrock DL, Zhao Z, Johnstone BM, Morris LS (2003) Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ. 6:67-75.
23. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP (1999) The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry. 60:649-657.
24. Miller AL, Craig CS (2002) Combination antipsychotics: Pros, cons, and questions. Schizophr Bull. 28:105-109.
25. National Institute for Clinical Excellence (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology appraisal guidance. London: National Institute for Clinical Excellence.
26. Novick D, Haro JM, Bertsch J, Haddad PM (2010) Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: Thirty-six-month results from the European Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 30:531-540.
27. Novick D, Haro JM, Perrin E, Suarez D, Texeira JM (2009b) Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol. 19:542-550.
28. Novick D, Haro JM, Suarez D, Vieta E, Naber D (2009a) Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 108:223-230.
29. Procyshyn RM, Kennedy NB, Tse G, Thompson B (2001) Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry. 46:334-339.
30. Stahl SM (2002) Antipsychotic polypharmacy: Squandering precious resources? J Clin Psychiatry. 63:93-94.
31. Suzuki T, Uchida H, Takeuchi H, Nomura K, Tanabe A, Watanabe K, Yagi G, Kashima H (2005) Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology (Berl). 181:566-575.
32. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study. BMJ. 333:224.
33. Wang PF, Zhao Z (2003) Comparison of olanzapine versus quetiapine in the treatment of hospitalized patients with schizophrenia. Value Health. 6:355.
34. Weissman EM (2002) Antipsychotic prescribing practices in the Veterans Healthcare AdministrationVNew York Metropolitan Region. Schizophr Bull. 28:31-42.
35. Wolff-Menzler C, Hasan A, Malchow B, Falkai P, Wobrock T (2010) Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry. 43:122-129.